Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

Aluna is a San Francisco-based digital health company founded in 2014, commercializing a connected, portable spirometer and software platform for respiratory disease management. Its core product is an FDA-cleared device for over-the-counter and prescription use, targeting both direct-to-consumer/patient markets and clinical research organizations. The company's value proposition centers on enabling proactive, at-home lung health monitoring to improve patient outcomes, reduce hospital visits, and provide reliable data for clinical trials, leveraging a platform that includes gamification for adherence and a provider dashboard for remote oversight.

AsthmaCystic Fibrosis

Technology Platform

Portable digital spirometer using a differential pressure sensor and proprietary machine learning algorithm for hospital-grade accuracy and effort quality assessment. Integrated with a patient app (for symptom/medication tracking and gamified engagement) and a provider/researcher dashboard for remote monitoring and data management.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The growing shift towards remote patient monitoring and value-based care creates a significant tailwind for Aluna's direct-to-patient model.
Simultaneously, the rapid adoption of decentralized clinical trial models presents a major B2B opportunity to provide reliable, remote spirometry data, reducing trial costs and improving participant retention.

Risk Factors

Key risks include navigating an uncertain reimbursement landscape for prescription use, competition in the growing digital respiratory health space, and the challenge of ensuring sustained patient adherence to daily monitoring.
As a custodian of sensitive health data, cybersecurity threats and data privacy breaches also pose a significant operational and reputational risk.

Competitive Landscape

Aluna competes in the digital spirometry and remote respiratory monitoring space against other startups (e.g., Propeller Health, now part of ResMed, offers sensor-enabled inhalers but not standalone spirometry) and established medtech companies with connected spirometers (e.g., Vitalograph, COSMED). Its focus on clinical trial support also pits it against traditional spirometry manufacturers and other decentralized trial technology providers.